These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 7635511)

  • 1. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-).
    Xu D; McSorley SJ; Chatfield SN; Dougan G; Liew FY
    Immunology; 1995 May; 85(1):1-7. PubMed ID: 7635511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis.
    Yang DM; Fairweather N; Button LL; McMaster WR; Kahl LP; Liew FY
    J Immunol; 1990 Oct; 145(7):2281-5. PubMed ID: 2144549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters.
    McSorley SJ; Xu D; Liew FY
    Infect Immun; 1997 Jan; 65(1):171-8. PubMed ID: 8975908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect on Leishmania major infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated Salmonella typhimurium.
    Xu D; McSorley SJ; Tetley L; Chatfield S; Dougan G; Chan WL; Satoskar A; David JR; Liew FY
    J Immunol; 1998 Feb; 160(3):1285-9. PubMed ID: 9570545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii.
    Cong H; Gu QM; Jiang Y; He SY; Zhou HY; Yang TT; Li Y; Zhao QL
    Parasite Immunol; 2005; 27(1-2):29-35. PubMed ID: 15813720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major.
    Xu D; Liew FY
    Immunology; 1995 Feb; 84(2):173-6. PubMed ID: 7750991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana.
    González CR; Noriega FR; Huerta S; Santiago A; Vega M; Paniagua J; Ortiz-Navarrete V; Isibasi A; Levine MM
    Vaccine; 1998; 16(9-10):1043-52. PubMed ID: 9682357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ISCOMs vaccine against experimental leishmaniasis.
    Papadopoulou G; Karagouni E; Dotsika E
    Vaccine; 1998; 16(9-10):885-92. PubMed ID: 9682333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice.
    Jaafari MR; Ghafarian A; Farrokh-Gisour A; Samiei A; Kheiri MT; Mahboudi F; Barkhordari F; Khamesipour A; McMaster WR
    Vaccine; 2006 Jul; 24(29-30):5708-17. PubMed ID: 16740346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits.
    Corthésy-Theulaz IE; Hopkins S; Bachmann D; Saldinger PF; Porta N; Haas R; Zheng-Xin Y; Meyer T; Bouzourène H; Blum AL; Kraehenbuhl JP
    Infect Immun; 1998 Feb; 66(2):581-6. PubMed ID: 9453612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection.
    Rivier D; Bovay P; Shah R; Didisheim S; Mauël J
    Parasite Immunol; 1999 Sep; 21(9):461-73. PubMed ID: 10476055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major.
    Yang DM; Rogers MV; Liew FY
    Immunology; 1991 Jan; 72(1):3-9. PubMed ID: 1997399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral mixed DNA vaccine protects mice from infection of Toxoplasma gondii].
    Cong H; Gu QM; Zhou HY; Guo L; Yang TT; He SY; Li Y; Zhao QL
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2005 Jun; 23(3):159-62. PubMed ID: 16300008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.
    Tonui WK; Mejia JS; Hochberg L; Mbow ML; Ryan JR; Chan AS; Martin SK; Titus RG
    Infect Immun; 2004 Oct; 72(10):5654-61. PubMed ID: 15385463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.